In situ bone regeneration with sequential delivery of aptamer and BMP2 from an ECM-based scaffold fabricated by cryogenic free-form extrusion
| Autor: | Xianglin Zhang, Qi Zhang, Wenqing Tian, Chunqing Meng, Xiaodong Guo, Tingfang Sun, Keda Yu, Qiuyue Ding, Zekang Xiong, Bin Wu, Wancheng Zhang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Scaffold
Aptamer QH301-705.5 Apt19s aptamer 19s BMD bone mineral density 0206 medical engineering Biomedical Engineering BMP2 Controlled delivery CSD critical-sized calvarial defect 02 engineering and technology Matrix (biology) Bone morphogenetic protein 2 Article SIS small intestine submucosa Biomaterials PVDF polyvinylidene difluoride BMP2 bone morphogenic protein 2 FBS fetal bovine serum Tissue engineering ssDNA single-stranded DNA Biology (General) Rh6G rhodamine 6G Bone regeneration Materials of engineering and construction. Mechanics of materials BMSC bone marrow-derived mesenchymal stem cell Decellularization FDA US Food and Drug Administration Chemistry 3D three-dimensional Mesenchymal stem cell CLSM confocal laser scanning microscopy ECM decellularized matrix PCL polycaprolactone 021001 nanoscience & nanotechnology 020601 biomedical engineering Cell recruitment Cell biology Transplantation FTIR Fourier transform infrared H&E hematoxylin and eosin HA hydroxyapatite TA401-492 FITC fluorescein isothiocyanate Bone regeneration in situ 0210 nano-technology pBMP2 PlGF-2123-144*-fused BMP2 Biotechnology |
| Zdroj: | Bioactive Materials, Vol 6, Iss 11, Pp 4163-4175 (2021) Bioactive Materials |
| Popis: | In situ tissue engineering is a powerful strategy for the treatment of bone defects. It could overcome the limitations of traditional bone tissue engineering, which typically involves extensive cell expansion steps, low cell survival rates upon transplantation, and a risk of immuno-rejection. Here, a porous scaffold polycaprolactone (PCL)/decellularized small intestine submucosa (SIS) was fabricated via cryogenic free-form extrusion, followed by surface modification with aptamer and PlGF-2123-144*-fused BMP2 (pBMP2). The two bioactive molecules were delivered sequentially. The aptamer Apt19s, which exhibited binding affinity to bone marrow-derived mesenchymal stem cells (BMSCs), was quickly released, facilitating the mobilization and recruitment of host BMSCs. BMP2 fused with a PlGF-2123-144 peptide, which showed “super-affinity” to the ECM matrix, was released in a slow and sustained manner, inducing BMSC osteogenic differentiation. In vitro results showed that the sequential release of PCL/SIS-pBMP2-Apt19s promoted cell migration, proliferation, alkaline phosphatase activity, and mRNA expression of osteogenesis-related genes. The in vivo results demonstrated that the sequential release system of PCL/SIS-pBMP2-Apt19s evidently increased bone formation in rat calvarial critical-sized defects compared to the sequential release system of PCL/SIS-BMP2-Apt19s. Thus, the novel delivery system shows potential as an ideal alternative for achieving cell-free scaffold-based bone regeneration in situ. Highlights • In current study, a sequential release system of PCL/SIS-pBMP2-Apt19s was designed to promote the homing and osteogenic differentiation of endogenous stem cells. •Compared with chemokines, growth factors, and peptides, aptamers Apt19s could specifically target endogenous stem cells BMSC and efficiently recruit cell homing. •The insertion of the PlGF-2123-144 domain to BMP2 (pBMP2) confers a super affinity to ECM-based materials. Thus, pBMP2 has a high ratio of retain in ECM-based materials, and possess a control release profile from ECM-based delivery system. •The novel scaffold PCL/SIS-pBMP2-Apt19s achieves cell-free scaffold-based bone regeneration in situ. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|